Ebola haemorrhagic fever.

Assessing the international spreading risk associated with the 2014 west african ebola outbreak. PLoS Curr (2014) 5.92

Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature (2011) 5.68

Mapping the zoonotic niche of Ebola virus disease in Africa. Elife (2014) 2.97

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med (2016) 2.88

The Contribution of Ebola Viral Load at Admission and Other Patient Characteristics to Mortality in a Médecins Sans Frontières Ebola Case Management Centre, Kailahun, Sierra Leone, June-October 2014. J Infect Dis (2015) 2.64

Ebola virus disease. BMJ (2014) 2.63

Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science (2015) 2.14

Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog (2012) 2.09

What factors might have led to the emergence of Ebola in West Africa? PLoS Negl Trop Dis (2015) 2.07

Safety and feasibility of a strategy of early central venous catheter insertion in a deployed UK military Ebola virus disease treatment unit. Intensive Care Med (2015) 2.05

Ebola outbreak response; experience and development of screening tools for viral haemorrhagic fever (VHF) in a HIV center of excellence near to VHF epicentres. PLoS One (2014) 2.01

Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe (2014) 2.00

Filoviruses in bats: current knowledge and future directions. Viruses (2014) 1.79

"A time of fear": local, national, and international responses to a large Ebola outbreak in Uganda. Global Health (2012) 1.74

Outbreaks of Ebola virus disease in Africa: the beginnings of a tragic saga. J Venom Anim Toxins Incl Trop Dis (2014) 1.72

Transmission of Ebola virus from pigs to non-human primates. Sci Rep (2012) 1.66

Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs (2013) 1.57

Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia. J Infect Dis (2015) 1.56

Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One (2012) 1.54

Ebola and Marburg hemorrhagic fevers: neglected tropical diseases? PLoS Negl Trop Dis (2012) 1.51

The intracellular cargo receptor ERGIC-53 is required for the production of infectious arenavirus, coronavirus, and filovirus particles. Cell Host Microbe (2013) 1.46

Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J Virol (2011) 1.46

The emergence of ebola as a global health security threat: from 'lessons learned' to coordinated multilateral containment efforts. J Glob Infect Dis (2014) 1.41

The Myeloid LSECtin Is a DAP12-Coupled Receptor That Is Crucial for Inflammatory Response Induced by Ebola Virus Glycoprotein. PLoS Pathog (2016) 1.39

Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial. PLoS One (2017) 1.39

Viruses acquired abroad: what does the primary care physician need to know? Dtsch Arztebl Int (2012) 1.38

Systematic review of the literature on viral persistence and sexual transmission from recovered Ebola survivors: evidence and recommendations. BMJ Open (2016) 1.35

Ebola Virus Glycoprotein with Increased Infectivity Dominated the 2013-2016 Epidemic. Cell (2016) 1.35

Ebola outbreak in rural West Africa: epidemiology, clinical features and outcomes. Trop Med Int Health (2015) 1.33

Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain. Emerg Infect Dis (2015) 1.31

Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J Clin Invest (2015) 1.30

Current ebola vaccines. Expert Opin Biol Ther (2012) 1.30

Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One (2013) 1.29

Inclusion bodies are a site of ebolavirus replication. J Virol (2012) 1.29

Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections. J Bioterror Biodef (2011) 1.28

A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Trop Dis (2011) 1.23

Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion. PLoS Negl Trop Dis (2011) 1.23

Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2. Proc Natl Acad Sci U S A (2011) 1.20

Deep sequencing identifies noncanonical editing of Ebola and Marburg virus RNAs in infected cells. MBio (2014) 1.20

The Current Mental Health Status of Ebola Survivors in Western Africa. J Clin Diagn Res (2015) 1.20

Ebolavirus in West Africa, and the use of experimental therapies or vaccines. BMC Biol (2014) 1.19

Understanding organ dysfunction in Ebola virus disease. Intensive Care Med (2014) 1.19

A Multi-Site Knowledge Attitude and Practice Survey of Ebola Virus Disease in Nigeria. PLoS One (2015) 1.17

Personal Protective Equipment: Protecting Health Care Providers in an Ebola Outbreak. Clin Ther (2015) 1.16

A comprehensive database of the geographic spread of past human Ebola outbreaks. Sci Data (2014) 1.16

Prognostic Indicators for Ebola Patient Survival. Emerg Infect Dis (2016) 1.15

Filovirus entry into cells - new insights. Curr Opin Virol (2012) 1.14

Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation. J Virol (2014) 1.14

A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity. J Virol (2014) 1.13

Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. Sci Rep (2016) 1.13

Ebola virus disease 2013-2014 outbreak in west Africa: an analysis of the epidemic spread and response. Int J Microbiol (2015) 1.12

An upstream open reading frame modulates ebola virus polymerase translation and virus replication. PLoS Pathog (2013) 1.12

Epidemiological and Surveillance Response to Ebola Virus Disease Outbreak in Lofa County, Liberia (March-September, 2014); Lessons Learned. PLoS Curr (2015) 1.11

Filoviral immune evasion mechanisms. Viruses (2011) 1.10

Identification of a New Ribonucleoside Inhibitor of Ebola Virus Replication. Viruses (2015) 1.10

A new player in the puzzle of filovirus entry. Nat Rev Microbiol (2012) 1.08

Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies. Antimicrob Agents Chemother (2014) 1.07

Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol (2015) 1.07

Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease. Virology (2011) 1.07

Interpretation of Negative Molecular Test Results in Patients With Suspected or Confirmed Ebola Virus Disease: Report of Two Cases. Open Forum Infect Dis (2015) 1.07

Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection. J Virol (2012) 1.06

Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog (2014) 1.06

Inhibition of Innate Immune Responses Is Key to Pathogenesis by Arenaviruses. J Virol (2016) 1.06

Gastrointestinal and Hepatic Manifestations of Ebola Virus Infection. Dig Dis Sci (2015) 1.06

Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther (2013) 1.05

Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. MBio (2014) 1.05

Risk factors for transmission of Ebola or Marburg virus disease: a systematic review and meta-analysis. Int J Epidemiol (2015) 1.05

A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals. Antiviral Res (2013) 1.04

Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers. Viruses (2012) 1.04

Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis (2011) 1.03

Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step. J Virol (2014) 1.02

Ebola viral disease and pregnancy. Obstet Med (2015) 1.02

How urbanization affects the epidemiology of emerging infectious diseases. Infect Ecol Epidemiol (2015) 1.02

Ebola virus transmission in guinea pigs. J Virol (2014) 1.01

Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. J Biol Chem (2011) 1.01

Ebolavirus vaccines for humans and apes. Curr Opin Virol (2012) 1.01

Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ (2015) 1.00

Modeling the transmission dynamics of Ebola virus disease in Liberia. Sci Rep (2015) 1.00

Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography. J Virol (2014) 0.99

Vaccines for viral hemorrhagic fevers--progress and shortcomings. Curr Opin Virol (2013) 0.99

The multiple roles of sGP in Ebola pathogenesis. Viral Immunol (2015) 0.98

Crystal structure of the Marburg virus GP2 core domain in its postfusion conformation. Biochemistry (2012) 0.98

A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection. MBio (2015) 0.97

Ebola Virus Disease: Experience and Decision Making for the First Patients outside of Africa. PLoS Med (2015) 0.97

Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers. MBio (2015) 0.97

Marburg virus glycoprotein GP2: pH-dependent stability of the ectodomain α-helical bundle. Biochemistry (2012) 0.97

Comparison of FilmArray and Quantitative Real-Time Reverse Transcriptase PCR for Detection of Zaire Ebolavirus from Contrived and Clinical Specimens. J Clin Microbiol (2015) 0.97

Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein. Chembiochem (2012) 0.97

Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge. ACS Chem Biol (2014) 0.97

In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol (2014) 0.96

Evidence of disseminated intravascular coagulation in a hemorrhagic fever with renal syndrome-scoring models and severe illness. PLoS One (2011) 0.96

Comparative Evaluation of the Diagnostic Performance of the Prototype Cepheid GeneXpert Ebola Assay. J Clin Microbiol (2015) 0.96

Ebola: translational science considerations. J Transl Med (2015) 0.96

A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs. Mol Pharm (2011) 0.95

Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect Dis Poverty (2014) 0.94

Discovery of an antibody for pan-ebolavirus therapy. Sci Rep (2016) 0.93

Development of RNA aptamers targeting Ebola virus VP35. Biochemistry (2013) 0.93

Phosphatidylserine receptors: enhancers of enveloped virus entry and infection. Virology (2014) 0.93

Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats. Elife (2015) 0.93

Assessing the Evidence Supporting Fruit Bats as the Primary Reservoirs for Ebola Viruses. Ecohealth (2015) 0.93

Fruit bats as reservoirs of Ebola virus. Nature (2005) 11.05

Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ (1978) 9.23

Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 8.32

A case of Ebola virus infection. Br Med J (1977) 7.40

The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis (1999) 7.39

The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A (1996) 7.02

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77

Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis (1999) 6.72

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35

Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog (2008) 6.07

Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol (2004) 5.86

Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med (1999) 5.85

Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ (1978) 5.82

The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A (2000) 5.46

GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology (1995) 5.34

Isolation and partial characterisation of a new strain of Ebola virus. Lancet (1995) 5.18

Epitopes involved in antibody-mediated protection from Ebola virus. Science (2000) 4.92

The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73

Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol (2003) 4.67

Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog (2009) 4.56

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet (2010) 4.52

A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis (1998) 4.50

Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med (2000) 4.36

Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol (1999) 4.32

Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis (1999) 4.28

Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis (2009) 4.24

Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis (1999) 4.18

Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis (1997) 4.03

ELISA for the detection of antibodies to Ebola viruses. J Infect Dis (1999) 3.92

High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J Infect Dis (2007) 3.74

Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69

Discovery of swine as a host for the Reston ebolavirus. Science (2009) 3.68

Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol (2002) 3.62

Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet (2003) 3.57

Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet (1990) 3.55

Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 3.50

Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis (1999) 3.47

Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol (1999) 3.44

Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome. Am J Epidemiol (1969) 3.39

Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med (2006) 3.38

Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis (1999) 3.36

Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis (2003) 3.33

Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis (2003) 3.15

[On the etiology of an unknown human infection originating from monkeys]. Dtsch Med Wochenschr (1967) 3.14

Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol (2004) 3.04

Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol (2004) 2.99

Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol (2002) 2.79

Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis (1999) 2.76

Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol (2003) 2.75

Ebola virus: from discovery to vaccine. Nat Rev Immunol (2003) 2.72

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol (2009) 2.71

Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl (1996) 2.69

Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis (2007) 2.68

Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64

Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58

Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest (2000) 2.45

Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. J Clin Microbiol (1982) 2.44

Molecular determinants of Ebola virus virulence in mice. PLoS Pathog (2006) 2.44

Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis (2007) 2.44

Designing a biocontainment unit to care for patients with serious communicable diseases: a consensus statement. Biosecur Bioterror (2006) 2.43

Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41

Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species. J Infect Dis (2007) 2.37

Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33

An introduction to Ebola: the virus and the disease. J Infect Dis (1999) 2.33

Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31

Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis (2002) 2.26

The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses. FEBS Lett (1992) 2.24

Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med (1996) 2.23

Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996. J Infect Dis (1999) 2.22

Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology (2000) 2.21

Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19

Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10

The ecology of Ebola virus. Trends Microbiol (2007) 2.08

Successful topical respiratory tract immunization of primates against Ebola virus. J Virol (2007) 2.06

Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett (2002) 2.06

Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis (1985) 2.02

Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2.01

A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis (1999) 1.96

Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol (2001) 1.94

Infection and activation of monocytes by Marburg and Ebola viruses. J Virol (2001) 1.90

Filoviridae: a taxonomic home for Marburg and Ebola viruses? Intervirology (1982) 1.89

Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain. J Infect Dis (1992) 1.84

Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One (2009) 1.83

Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol (1999) 1.83

Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol (2008) 1.78

Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol (2010) 1.77

Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. Virology (1998) 1.73

AIDS research. Did Merck's failed HIV vaccine cause harm? Science (2007) 1.71

Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection. J Infect Dis (1999) 1.70

Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol (1999) 1.68

An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis (1999) 1.67

Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis (1989) 1.65

Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic. Arch Virol Suppl (1996) 1.58

A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol (2006) 1.58

Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon. Emerg Infect Dis (1997) 1.56

Laboratory diagnosis of Ebola and Marburg hemorrhagic fever. Bull Soc Pathol Exot (2005) 1.54

Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch Virol (1996) 1.53

Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis (2007) 1.53

Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol (1985) 1.52

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35

Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med (2002) 3.88

Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 3.77

Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69

Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis (2007) 3.51

Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15

Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64

Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis (2007) 2.44

Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol (2005) 2.27

Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett (2002) 2.06

Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe (2013) 1.97

The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A (2004) 1.85

Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85

CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med (2011) 1.83

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 1.81

Framework for leadership and training of Biosafety Level 4 laboratory workers. Emerg Infect Dis (2008) 1.66

Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 1.62

Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines (2011) 1.62

An optofluidic nanoplasmonic biosensor for direct detection of live viruses from biological media. Nano Lett (2010) 1.57

Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol (2004) 1.55

Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis (2007) 1.53

Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J Infect Dis (2007) 1.52

Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis (2011) 1.47

Development of vaccines for Marburg hemorrhagic fever. Expert Rev Vaccines (2007) 1.45

In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis (2007) 1.43

A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med (2011) 1.35

MassTag polymerase chain reaction for differential diagnosis of viral hemorrhagic fever. Emerg Infect Dis (2006) 1.35

Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis (2012) 1.32

Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections. J Bioterror Biodef (2011) 1.28

Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis (2012) 1.27

Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques. J Infect Dis (2011) 1.26

A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J Virol (2010) 1.21

A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med (2012) 1.20

Outbreaks of filovirus hemorrhagic fever: time to refocus on the patient. J Infect Dis (2007) 1.20

The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol (2007) 1.20

Viral hemorrhagic fevers. Clin Lab Med (2006) 1.18

Label-free multiplexed virus detection using spectral reflectance imaging. Biosens Bioelectron (2011) 1.18

Pathogenesis of Lassa fever in cynomolgus macaques. Virol J (2011) 1.16

Epitopes required for antibody-dependent enhancement of Ebola virus infection. J Infect Dis (2007) 1.16

Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis (2007) 1.12

Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA. J Infect Dis (2013) 1.12

Potential impact of a 2-person security rule on BioSafety Level 4 laboratory workers. Emerg Infect Dis (2009) 1.11

Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. Viral Immunol (2015) 1.09

Inhibition of heat-shock protein 90 reduces Ebola virus replication. Antiviral Res (2010) 1.04

Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis (2011) 1.03

A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral Res (2013) 1.02

Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. J Virol (2007) 1.00

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest (2015) 0.99

Cellular immune response to Marburg virus infection in cynomolgus macaques. Viral Immunol (2008) 0.96

Therapeutics of Ebola hemorrhagic fever: whole-genome transcriptional analysis of successful disease mitigation. J Infect Dis (2011) 0.96

Interferon-beta 1a and SARS coronavirus replication. Emerg Infect Dis (2004) 0.95

A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques. J Infect Dis (2013) 0.94

Ebola and Marburg viruses: pathogenesis and development of countermeasures. Curr Mol Med (2005) 0.93

The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. Thromb Haemost (2005) 0.87

Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg Infect Dis (2015) 0.86

Immunization strategies against henipaviruses. Curr Top Microbiol Immunol (2012) 0.83

Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus' soluble glycoprotein. Immunogenetics (2005) 0.81

A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge. J Virol (2014) 0.81

Animal models for highly pathogenic emerging viruses. Curr Opin Virol (2013) 0.80

Safety of recombinant VSV-Ebola virus vaccine vector in pigs. Emerg Infect Dis (2015) 0.79

Development of treatment strategies to combat Ebola and Marburg viruses. Expert Rev Anti Infect Ther (2006) 0.78

Detection and identification of Variola virus in fixed human tissue after prolonged archival storage. Lab Invest (2004) 0.78

Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase. Res Sq (2020) 0.75

In plain sight: the role of alpha-1-antitrypsin in COVID-19 pathogenesis and therapeutics. bioRxiv (2020) 0.75

Emerging viruses: advances and challenges. Curr Mol Med (2005) 0.75